Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines - PubMed (original) (raw)
Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines
C L Collins et al. J Cell Physiol. 1998 Jul.
Abstract
A continual supply of the amino acid glutamine (GLN) may be necessary for cancerous cell growth. GLN plays a central role in multiple metabolic pathways and has long been considered an essential component of tissue culture media. However, the GLN requirements of tumor cell lines and the factors that determine a cell's need for GLN have not been comprehensively studied. Also, it remains unclear how various metabolic pathways contribute to GLN consumption. In the present study, possible determinants of GLN metabolism were examined in seven breast cell lines, two derived from immortalized normal tissue and five of tumor origin. These cells exhibited different dependencies on media GLN concentration for growth and a wide range of GLN utilization rates. GLN uptake was facilitated by a single, common transporter functionally defined as System ASC. However, the affinities for GLN exhibited by this transporter differed appreciably between cell lines. Furthermore, the concentration at which media GLN became a limiting factor for cellular proliferation correlated with transporter affinity. The origin of the cell lines was not a determinant of GLN metabolism because immortalized cells of nontumor origin exhibited GLN dependence and utilization rates comparable to those of tumor-derived cells. The rates of CO2 production from GLN were similar for each cell lines. Rates of GLN disappearance and glutamate appearance in media were strongly correlated, with 32-80% of media GLN converted to glutamate. Both rates were directly affected by media cystine concentration, suggesting that a large portion of glutamate efflux was coupled with cystine import through the amino acid transport system x(c)-. These results demonstrated that cell growth is a function of GLN influx and suggest that GLN is used to supply glutamate and cystine, perhaps for glutathione synthesis.
Similar articles
- Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells.
Meadows AL, Kong B, Berdichevsky M, Roy S, Rosiva R, Blanch HW, Clark DS. Meadows AL, et al. Biotechnol Prog. 2008 Mar-Apr;24(2):334-41. doi: 10.1021/bp070301d. Epub 2008 Feb 29. Biotechnol Prog. 2008. PMID: 18307352 - Transport of L-[14C]cystine and L-[14C]cysteine by subtypes of high affinity glutamate transporters over-expressed in HEK cells.
Hayes D, Wiessner M, Rauen T, McBean GJ. Hayes D, et al. Neurochem Int. 2005 Jun;46(8):585-94. doi: 10.1016/j.neuint.2005.03.001. Epub 2005 Apr 12. Neurochem Int. 2005. PMID: 15863236 - A novel function of glutamine in cell culture: utilization of glutamine for the uptake of cystine in human fibroblasts.
Bannai S, Ishii T. Bannai S, et al. J Cell Physiol. 1988 Nov;137(2):360-6. doi: 10.1002/jcp.1041370221. J Cell Physiol. 1988. PMID: 2903864 - Glutamine and glutamate--their central role in cell metabolism and function.
Newsholme P, Procopio J, Lima MM, Pithon-Curi TC, Curi R. Newsholme P, et al. Cell Biochem Funct. 2003 Mar;21(1):1-9. doi: 10.1002/cbf.1003. Cell Biochem Funct. 2003. PMID: 12579515 Review. - The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.
Lo M, Wang YZ, Gout PW. Lo M, et al. J Cell Physiol. 2008 Jun;215(3):593-602. doi: 10.1002/jcp.21366. J Cell Physiol. 2008. PMID: 18181196 Review.
Cited by
- Novel therapeutic targets of tumor metabolism.
Kishton RJ, Rathmell JC. Kishton RJ, et al. Cancer J. 2015 Mar-Apr;21(2):62-9. doi: 10.1097/PPO.0000000000000099. Cancer J. 2015. PMID: 25815845 Free PMC article. Review. - Reduced stress tolerance of glutamine-deprived human monocytic cells is associated with selective down-regulation of Hsp70 by decreased mRNA stability.
Eliasen MM, Brabec M, Gerner C, Pollheimer J, Auer H, Zellner M, Weingartmann G, Garo F, Roth E, Oehler R. Eliasen MM, et al. J Mol Med (Berl). 2006 Feb;84(2):147-58. doi: 10.1007/s00109-005-0004-6. Epub 2005 Nov 25. J Mol Med (Berl). 2006. PMID: 16308684 - Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Timmerman LA, et al. Cancer Cell. 2013 Oct 14;24(4):450-65. doi: 10.1016/j.ccr.2013.08.020. Epub 2013 Oct 3. Cancer Cell. 2013. PMID: 24094812 Free PMC article. - Increased Ammonium Toxicity in Response to Exogenous Glutamine in Metastatic Breast Cancer Cells.
Kiesel VA, Sheeley MP, Donkin SS, Wendt MK, Hursting SD, Teegarden D. Kiesel VA, et al. Metabolites. 2022 May 23;12(5):469. doi: 10.3390/metabo12050469. Metabolites. 2022. PMID: 35629973 Free PMC article. - IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growth.
Venmar KT, Kimmel DW, Cliffel DE, Fingleton B. Venmar KT, et al. Biochim Biophys Acta. 2015 May;1853(5):1219-28. doi: 10.1016/j.bbamcr.2015.02.020. Epub 2015 Mar 4. Biochim Biophys Acta. 2015. PMID: 25746764 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous